Abstract:Neutrophil extracellular traps (NETs) immobilize pathogens during early stages of systemic inflammation but as the reaction progresses they become detrimental to endothelial cells and the organ-specific cells. For this reason it would be of importance to control their formation by either physiological or pharmacological means. Endogenously, formation of NETs is under control of cellular and whole organism metabolism as shown previously in the course of bacterial systemic inflammation, obesity or the combination of the two. Numerous leukocytes are subjected to immunometabolic regulation and in macrophages exposure to lipopolysaccharide (LPS) leads to two breaks in the Krebs cycle that impact this cell functioning. As a consequence of the first break, anti-microbial itaconic acid (itaconate) is produced whereas the second break activates hypoxia-inducible factor-1α (Hif-1α). In turn, itaconate activates transcription of the anti-inflammatory nuclear factor erythroid 2-related factor 2 (Nrf2) which upregulates cyto-protective heme oxygenase (HO-1). Here we report that exogenously added derivative of the itaconic acid, 4-octyl itaconate (4-OI), diminishes formation of NETs by neutrophils of either normal (lean) or obese mice, and independently of the age of the animals or immunoaging. Elucidating the mechanism of this inhibition we unravel that although Nrf2/HO-1 expression itself is not altered by 4-OI, it is up-regulated when compared against the NET formation while Hif-1α is downregulated in 4-OI-pre-treated LPS-stimulated neutrophils in either way. We further show that blockage of Hif-1α by its specific inhibitor diminishes NET release as does inhibition by 4-OI. Also inhibition of HO-1 activity correlates with diminished LPS-induced NET release upon pre-treatment with 4-OI albeit LPS alone induced NETs are not HO-1-dependent. In summary, we unravel that 4-OI inhibits NET formation by murine neutrophils independently of their origin (health vs. metabolically challenged animals) and the age of individuals/immunosenescence via inhibition of Hif-1α and induction of HO-1.

Endogenous itaconate is not required for particulate matter-induced NRF2 expression or inflammatory response

Itaconate Regulates Macrophage Function Through Stressful Iron-Sulfur Cluster Disrupting And Iron Metabolism Rebalancing

Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1

Itaconate is a Lysosomal Inducer That Promotes Antibacterial Innate Immunity.

The immunometabolite itaconate inhibits heme synthesis and remodels cellular metabolism in erythroid precursors

The Cell Autonomous and Non-Autonomous Roles of Itaconate in Immune Response

Itaconate Uptake Via SLC13A3 Improves Hepatic Antibacterial Innate Immunity

Itaconate as a Promising Therapy for Neuropathic Pain and Inflammatory Pain

Endogenously produced itaconate negatively regulates innate-driven cytokine production and drives global ubiquitination in human macrophages

Itaconate stabilizes CPT1a to enhance lipid utilization during inflammation

Itaconate Suppresses Formation of Neutrophil Extracellular Traps (NETs): Involvement of Hypoxia-Inducible Factor 1α (Hif-1α) and Heme Oxygenase (HO-1)

Acod1/itaconate activates Nrf2 in pulmonary microvascular endothelial cells to protect against the obesity-induced pulmonary microvascular endotheliopathy

Itaconate: A Metabolite Regulates Inflammation Response and Oxidative Stress

Itaconate suppresses house dust mite-induced allergic airways disease and Th2 cell differentiation

Itaconate and dimethyl itaconate upregulate IL-6 production in the LPS-induced inflammation in mice

Deficiency of IRG1/ itaconate aggravates endotoxemia-induced acute lung injury by inhibiting autophagy in mice

Control of immune cell signaling by the immuno-metabolite itaconate

Itaconate drives mtRNA-mediated type I interferon production through inhibition of succinate dehydrogenase

Itaconate inhibits ferroptosis of macrophage via Nrf2 pathways against sepsis-induced acute lung injury

The potential of using itaconate as treatment for inflammation-related heart diseases

Metabolite itaconate in host immunoregulation and defense